Aug 19, 2024, 11:57
Katsuaki Maehara: Interesting indirect comparison analysis for Melanoma
Katsuaki Maehara shared a post on X:
“Melanoma Journal of Clinical Oncology.
- NCCN Guidelines recommended both Nivo+ Rela and Nico + Ipi as preferred, category 1, first-line systemic therapy options for unresectable or metastatic melanoma.
- An interesting INDIRECT comparison analysis has been published.”
- No difference in efficacy has been observed, but there are indications that Nivo + Rela tends to be better in terms of safety.
Authors: Georgina V. Long, Evan J. Lipson, F. Stephen Hodi, Paolo A. Ascierto, James Larkin, Christopher Lao, Jean-Jacques Grob, Flavia Ejzykowicz, Andriy Moshyk3, Viviana Garcia-Horton, Zheng-Yi Zhou, Yiqiao Xin, Jennell Palaia, Laura McDonald, Sarah Keidel, Anthony Salvatore, Divya Patel, Leon A. Sakkal, Hussein Tawbi, and Dirk Schadendorf.
Source: Katsuaki Maehara/X
Aug 19, 2024, 11:47